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FIGURE 1. All cause mortality (A, risk ratio; B, hazard ratio) among patients with early-stage non-small cell lung cancer randomized to mediastinal lymph
node dissection (MLND) versus sampling (MLNS) during pulmonary resection. IV, Inverse variance;CI, confidence interval; ACOSOG,American College of
Surgery Oncology Group; SE, standard error.
Letters to the EditorStudies considered for inclusion met
the following criteria: the design was
a prospective randomized controlled
clinical trial; the study population was
patients with early-stage (stage I–IIIA)
NSCLC; patients were randomly as-
signed to MLND versus MLNS during
pulmonary resection; and main out-
comes included follow-up all-cause
mortality.For each study, data regarding
all-cause mortality in both the MLND
and MLNS groups were used to gener-
ate risk ratios (RRs) and 95% confi-
dence intervals (CIs). Hazard ratios
(HRs) for all-cause death and 95%
CIswere also abstracted fromeach indi-
vidual study. Study-specific estimates
were combined using inverse variance-
weighted averages of logarithmic RRs
or HRs in both fixed- and random-
effects models. Where no significant
statistical heterogeneity was identified,
the fixed-effect estimate was used pref-
erentially as the summary measure.
Our comprehensive search (current
through March 2011) identified 4 trials:
median6.5-year results of theACOSOG
Z0030 trial,1 10-year results of a trial by
Wu and associates,2median 5.4-year re-
sults of a trial by Sugi and colleagues,3
and median 4.0-year results of a trial
by Izbicki and collaborators.4 Pooled
analysis of the 4 trials (representing478 The Journal of Thoracic and C1778 patients with early-stage NSCLC)
demonstrated a statistically nonsignifi-
cant reduction (but a strong trend toward
a significant reduction) in all-causemor-
tality with MLND relative to MLNS in
fixed-effects models (RR, 0.91; 95%
CI, 0.82-1.00; P ¼ .05; P for heteroge-
neity ¼ .59 [Figure 1, A]; HR, 0.86;
95% CI, 0.73-1.01; P¼ .06; P for het-
erogeneity ¼ .29 [Figure 1, B]). Exclu-
sion of any single trial of the previous
3 trials2-4 from the analysis did not sub-
stantively alter the overall result of our
analysis. Eliminating the ACOSOG
Z0030 trial,1 however, demonstrated
a statistically significant reduction in
all-cause mortality withMLND relative
to MLNS (RR, 0.87; 95% CI, 0.76-
0.99; P ¼ .04; HR, 0.69; 95% CI,
0.51-0.93; P¼ .01).
The results of the present analysis
suggest that MLND may not reduce
all-cause mortality over MLNS during
pulmonary resection in patients with
early-stage NSCLC. The results are
not robust, however, because exclu-
sion of the ACOSOG Z0030 trial1
substantially changed the pooled esti-
mate. Which way we ought to walk
from here depends a good deal on
where we want to get to.
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We read with interest the letter of
Takagi, Matsui, and Umemoto, who
provided the results of their meta-
analyses of randomized controlled tri-
als of mediastinal lymph node
Letters to the Editordissection (MLND) versus mediastinal
lymph node sampling (MLNS) during
pulmonary resection. The 4 trials that
were included in the meta-analyses in-
cluded the American College of Sur-
gery Oncology Group (ACOSOG)
Z0030 trial1 as well as trials reported
by Wu,2 Sugi,3 Izbicki,4 and their co-
workers. All of these trials addressed
the question of whether MLND im-
proved survival after pulmonary resec-
tion for lung cancer compared with
MLNS.
In the Izbicki trial,4 patients with re-
sectable non–small cell lung cancer
(NSCLC) stages I, II, or IIIA were
staged preoperatively with computed
tomography but had mediastinoscopy
only if they had enlarged contralateral
(N3) nodes. Patients were randomized
at thoracotomy to MLNS or MLND.
This methodology differs from that
used in the ACOSOG trial, wherein
only patientswho hadnegative system-
atic sampling of stations 2R, 4R, 7, and
10R for right-sided tumors and 5, 6, 7,
and 10L for left-sided tumors were el-
igible for randomization. In this way,
patients with N2 postive nodes that
were discovered with sampling were
excluded from the trial.
In the trial reported by Sugi and as-
sociates,3 only patients with small T1
(<2 cm; stage Ia) NSCLC were in-
cluded, but a similar protocol to that
used in the Izbicki trial was used (ie,
invasive mediastinal node assessment
was not done before randomization).
The ACOSOG trial1 included patients
with clinical stages I and II, although
the majority of patients had stage I
disease with approximately equal pro-
portions of stage Ia and Ib.
In the trial reported by Wu and co-
workers,2 only clinical staging was
performed before randomization; no
invasive mediastinal staging was per-
formed before randomization, with
the result that 40% of patients in the
MLND group had stage IIIa disease
versus 28% in the MLNS group.
Takagi and colleagues report
a strong trend to improved survival in
their meta-analysis of the 4 trials withThe Journala relative risk (RR) of 0.91 (95% con-
fidence interval [CI], 0.82-1.0), but if
the ACOSOG trial is excluded, the re-
sult changes with a RR of 0.87 [95%
CI, 0.76-0.99; P ¼ .04]. The non-
ACOSOG trials are all similar in that
invasive staging of the mediastinum
was not done before randomization.
How, then, should we interpret these
results? It appears that if invasive me-
diastinal lymph node assessment is not
done before resection (ie, no mediasti-
noscopy and no mediastinal lymph no-
des sampling), then an MLND should
be performed as it potentially offers
a survival advantage largely because
of the detection and removal of posi-
tive mediastinal nodes. However, if
the surgeon has systematically staged
the mediastinum either by mediastino-
scopy or by sampling at the time of
pulmonary resection for T1 or T2
NSCLC by thoracotomy or video-
assisted thoracic surgery and there is
no evidence of N2 disease, then
MLND by formal en bloc resection
adds nothing further and offers no sur-
vival advantage.
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TWO-DIMENSIONAL AND
COLOR DOPPLER
ECHOCARDIOGRAPHIC
GUIDANCE ENABLE ROUTINE
ASCENDING AORTIC
CANNULATION IN TYPE A
ACUTE AORTIC DISSECTION
To the Editor:
We readwith great interest the recent
article by Inoue and associates1 describ-
ing routine ascending aortic cannula-
tion in type A acute dissection with
the guidance of epiaortic scanning.
Over the past year, we have started
adopting a similar strategy as a routine
in type A aortic dissection. The proce-
dure has been used in 7 consecutive
patients so far with no complications
related to cannulation. As we read
the authors’ impressive work,1 we
pondered over queries regarding 2
main differences in our technique.
First, transesophageal echocardiog-
raphy (TEE) is a valuable adjunct to
the procedure. In our practice, intrao-
perative TEE is routinely used in
type A dissection, so we relied on
a combination of TEE and epiaortic
scanning to assist in direct cannulation
of the aorta. TEE, apart from its nu-
merous diagnostic capacities in such
cases, may be a valuable adjunct to
this specific procedure. It allows con-
firmation of the position of the guide-
wire and the cannula in the distal arch
or descending aorta, as well as the
flow in the true lumen when the arte-
rial line is tested immediately after
cannulation. The use of TEE in such
a setting was previously described by
G€ob€ol€os and colleagues,2 although
they described it without the use of ep-
iaortic scanning and as a bail-out,
rather than a routine procedure.
Second, we noticed that the authors1
repeatedly highlighted the value of de-
compression of the aorta by instituting
femoro-atrial bypass before ascendingry c Volume 142, Number 2 479
